Teriparatide biosimilar - USV
Alternative Names: Recombinant parathyroid hormone biosimilar - USVLatest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator USV
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 05 Sep 2017 No recent reports on development identified - Registered for Osteoporosis in India (Injection)
- 09 May 2015 USV files a patent for teriparatide biosimilar before May 2015 (USV product pipeline, May 2015)